* admitted to hospital or in an ed for more than 24 hours * previously randomized to cantreatcovid * currently participating in a clinical trial of a therapeutic agent for acute sars-cov-2 infection that is not/suspected not compatible with the study therapeutics * already taking a study therapeutic or contraindication to a study therapeutic * inability for participant or caregiver to provide informed consent paxlovid exclusion criteria include: * history of clinically significant hypersensitivity to the active substances in paxlovid™ (nirmatrelvir /ritonavir) or to any of its excipients. * patients with known rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. * patients with known current severe liver impairment (characterized by severe ascites, encephalopathy, jaundice, or prolonged inr. people with liver disease without any of these features are eligible). * is a recipient of a solid organ transplant and taking immunosuppressant medications. * patients with known moderate or severe renal disease (defined as ckd stage 3, 4 or 5 or current acute kidney injury or most recent egfr in the past 6 months \<60 ml/min). * currently taking paxlovid™. * clinical requirement to continue taking a drug which is contraindicated or not recommended for administration with paxlovid™ in the context of cantreatcovid or is taking a drug which in the opinion of the investigator would put the subject at unacceptable risk. * has a known or suspected pregnancy. * is breastfeeding. * is of childbearing potential and is not willing to use a highly effective contraceptive antioxidant exclusion criteria include: * has a known or suspected pregnancy. * is breastfeeding. * is of childbearing potential and is not willing to use a highly effective contraceptive. * has allergy or intolerance to selenium, zinc, lycopene, vitamin c, ascorbyl palmitate, hypromellose, microcrystalline cellulose, or sodium stearyl fumarate * is taking warfarin as a preventive measure. * has advanced chronic kidney disease (ckd stage 3: egfr ≥30 to \<60 ml/min, and severe renal impairment (egfr \<30 ml/min, ckd stage 4-5) * has liver disease awaiting transplantation. * has a history of calcium oxalate kidney stones. * has a diagnosis of head and neck cancer within the past 5 years * has medical history of non-melanoma skin cancer * is taking selenium (≥300ug/day), zinc (≥40mg/day), lycopene (≥45mg/day), and vitamin c (≥1500mg/day) supplements at baseline * is consuming omega-3 fatty acids at baseline and is unwilling to stop during the intervention period.

* admitted to hospital or in an ed for more than 24 hours * previously randomized to cantreatcovid * currently participating in a clinical trial of a therapeutic agent for acute sars-cov-2 infection that is not/suspected not compatible with the study therapeutics * already taking a study therapeutic or contraindication to a study therapeutic * inability for participant or caregiver to provide informed consent paxlovid exclusion criteria include: * history of clinically significant hypersensitivity to the active substances in paxlovid™ (nirmatrelvir /ritonavir) or to any of its excipients. * patients with known rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. * patients with known current severe liver impairment (characterized by severe ascites, encephalopathy, jaundice, or prolonged inr. people with liver disease without any of these features are eligible). * is a recipient of a solid organ transplant and taking immunosuppressant medications. * patients with known moderate or severe renal disease (defined as ckd stage 3, 4 or 5 or current acute kidney injury or most recent egfr in the past 6 months \<60 ml/min). * currently taking paxlovid™. * clinical requirement to continue taking a drug which is contraindicated or not recommended for administration with paxlovid™ in the context of cantreatcovid or is taking a drug which in the opinion of the investigator would put the subject at unacceptable risk. * has a known or suspected pregnancy. * is breastfeeding. * is of childbearing potential and is not willing to use a highly effective contraceptive antioxidant exclusion criteria include: * has a known or suspected pregnancy. * is breastfeeding. * is of childbearing potential and is not willing to use a highly effective contraceptive. * has allergy or intolerance to selenium, zinc, lycopene, vitamin c, ascorbyl palmitate, hypromellose, microcrystalline cellulose, or sodium stearyl fumarate * is taking warfarin as a preventive measure. * has advanced chronic kidney disease (ckd stage 3: egfr ≥30 to \<60 ml/min, and severe renal impairment (egfr \<30 ml/min, ckd stage 4-5) * has liver disease awaiting transplantation. * has a history of calcium oxalate kidney stones. * has a diagnosis of head and neck cancer within the past 5 years * has medical history of non-melanoma skin cancer * is taking selenium (≥300ug/day), zinc (≥40mg/day), lycopene (≥45mg/day), and vitamin c (≥1500mg/day) supplements at baseline * is consuming omega-3 fatty acids at baseline and is unwilling to stop during the intervention period.

* admitted to hospital or in an ed for more than 24 hours * previously randomized to cantreatcovid * currently participating in a clinical trial of a therapeutic agent for acute sars-cov-2 infection that is not/suspected not compatible with the study therapeutics * already taking a study therapeutic or contraindication to a study therapeutic * inability for participant or caregiver to provide informed consent paxlovid

* admitted to hospital or in an ed for more than 24 hours * previously randomized to cantreatcovid * currently participating in a clinical trial of a therapeutic agent for acute sars-cov-2 infection that is not/suspected not compatible with the study therapeutics * already taking a study therapeutic or contraindication to a study therapeutic * inability for participant or caregiver to provide informed consent paxlovid

admitted to hospital or in an ed for more than 24 hours previously randomized to cantreatcovid currently participating in a clinical trial of a therapeutic agent for acute sars-cov-2 infection that is not/suspected not compatible with the study therapeutics already taking a study therapeutic or contraindication to a study therapeutic inability for participant or caregiver to provide informed consent paxlovid

admitted to hospital or in an ed for more than 24 hours previously randomized to cantreatcovid currently participating in a clinical trial of a therapeutic agent for acute sars-cov-2 infection that is not/suspected not compatible with the study therapeutics already taking a study therapeutic or contraindication to a study therapeutic inability for participant or caregiver to provide informed consent paxlovid